Richard Nolan Townsend Sells 4,326 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 4,326 shares of Lexeo Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $4.41, for a total value of $19,077.66. Following the completion of the transaction, the chief executive officer now owns 220,119 shares in the company, valued at $970,724.79. This represents a 1.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Richard Nolan Townsend also recently made the following trade(s):

• On Tuesday, December 10th, Richard Nolan Townsend sold 2,500 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $8.20, for a total value of $20,500.00.

Lexeo Therapeutics Stock Down 3.5 %

Shares of LXEO stock opened at $3.89 on Monday. Lexeo Therapeutics, Inc. has a fifty-two week low of $3.84 and a fifty-two week high of $19.50. The stock’s 50-day simple moving average is $5.70 and its 200-day simple moving average is $8.03. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The firm has a market capitalization of $128.64 million, a PE ratio of -1.23 and a beta of 2.99.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. Leerink Partners reduced their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 13th. HC Wainwright increased their price objective on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. Finally, Chardan Capital boosted their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $23.80.

Institutional Trading of Lexeo Therapeutics

Large investors have recently made changes to their positions in the business. Allostery Investments LP purchased a new position in shares of Lexeo Therapeutics during the fourth quarter worth $33,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Lexeo Therapeutics during the 4th quarter valued at about $46,000. BNP Paribas Financial Markets raised its stake in shares of Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the last quarter. Values First Advisors Inc. purchased a new stake in shares of Lexeo Therapeutics in the third quarter worth about $67,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Lexeo Therapeutics in the fourth quarter worth about $69,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.